Physician profile
Daniel Cordoba
NPI 1760860738
$2,404.18
in general payments reported to CMS, 2019-2025
24 companies · $623 in 2025
The $623 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.24 · 2021: $335 · 2022: $461 · 2023: $343 · 2024: $628 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548 · Education: $45.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.33 |
| Education | $45.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $424.07 | 2021-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $268.48 | 2023-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $248.64 | 2021-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.72 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $173.81 | 2021-2025 | |
| Amgen INC. | $144.02 | 2022-2023 | Tavneos |
| Akebia Therapeutics INC | $137.79 | 2025 | Vafseo, Auryxia |
| Takeda Pharmaceuticals U.S.A., INC. | $136.73 | 2021-2023 | Gattex |
| Radius Health, INC. | $100.95 | 2022 | |
| Novo Nordisk INC | $81.84 | 2024-2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $73.90 | 2021-2023 | Ultomiris |
| Travere Therapeutics, INC. | $63.69 | 2024-2025 | |
| Horizon Therapeutics Plc | $50.92 | 2021-2022 | |
| Glaxosmithkline, LLC. | $41.98 | 2022-2023 | Benlysta |
| Veloxis Pharmaceuticals, INC. | $38.75 | 2023 | Envarsus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $30.63 | 2024 | Defencath |
| Fresenius USA Marketing, INC. | $26.92 | 2021-2022 | |
| Dexcom, INC. | $22.89 | 2024 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $21.15 | 2024 | Veltassa |
| Outset Medical INC | $20.84 | 2023 | |
| Lilly USA, LLC | $19.75 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2024 | Lupkynis |
| Scpharmaceuticals INC. | $17.78 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cordoba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.